Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00062699 · ClinicalTrials.gov registry record · Phase 4
Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis
A Phase 4 study, sponsored by Abbott.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2,200
- Enrollment target
NCT00062699 is a Phase 4 study that was terminated before completion, run by Abbott. The registered enrollment target is 2,200 participants.
The verdict
NCT00062699, a Phase 4 study, was terminated before completion, sponsored by Abbott.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2,200 participants
- Enrollment target
Study Summary
To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
Interventions
- DRUG Zemplar (paricalcitol injection)
- DRUG Calcijex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2003-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00062699
The ClinicalTrials.gov registry entry for NCT00062699 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zemplar (paricalcitol injection) is the first listed.
NCT00062699 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00062699 about?
NCT00062699 is a clinical study titled "Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis". To evaluate the survival benefit associated with Zemplar therapy as compared to Calcijex for the treatment of secondary hyperparathyroidism in subjects with Stage V chronic kidney disease on hemodialysis as measured by time to death.
What is the current status of trial NCT00062699?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2,200 participants. The study started on 2003-04.
What interventions are being tested in trial NCT00062699?
The interventions under investigation include: Zemplar (paricalcitol injection) (DRUG), Calcijex (DRUG).
Who is sponsoring clinical trial NCT00062699?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.